President-elect Trump selected Jay Bhattacharya, Stanford professor and Covid-19 lockdown critic, to lead NIH, and Jim ...
Alladapt Immunotherapeutics, a well-financed biotech working in the food allergy field, shut down following talks with the ...
FDA extends review of Soleno Therapeutics' diazoxide choline extended-release tablets for Prader-Willi syndrome by three ...
Amgen’s long-anticipated weight loss data are here, with MariTide spurring an average of 20% weight loss after one year for ...
The Biden administration proposed a new rule Tuesday that would expand Medicare and Medicaid coverage of popular ...
Roche's tiragolumab failed to meet overall survival endpoint in Phase 3 SKYSCRAPER-01 trial when combined with Tecentriq for ...
Roche is acquiring its cell therapy and genomic medicines partner Poseida Therapeutics, the companies said Tuesday morning.
Aviceda seeks $200M for AVD-104 trial, Nerviano reacquires NMS-293 from Merck KGaA, MaaT Pharma reports positive Phase 1b ALS drug data, Secretome raises $20.4M, 35Pharma secures $35M Series C, ...
Agilent Technologies announced reorganization into three business units: life sciences and diagnostics led by Simon May, ...
Biohaven's Phase 3 trial of taldefgrobep alfa failed to meet its primary endpoint in spinal muscular atrophy, causing a 10% ...
Merck is ending Phase 3 trial of Winrevair (sotatercept) early due to positive interim results in treating pulmonary arterial ...
Gilead acquires HTI T-cell immunogen HIV vaccines from Barcelona's Aelix Therapeutics for an undisclosed amount. The vaccines ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback